Patents by Inventor Mark Erlander
Mark Erlander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7179604Abstract: DNAs encoding the human histamine H3 receptor have been cloned and characterized. The recombinant protein is capable of forming biologically active histamine H3 receptor protein. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.Type: GrantFiled: December 2, 2003Date of Patent: February 20, 2007Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Timothy W. Lovenberg, Mark Erlander, Arne Huvar, Jayashree Pyati
-
Publication number: 20070020655Abstract: The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.Type: ApplicationFiled: June 2, 2006Publication date: January 25, 2007Applicant: AviaraDx, Inc.Inventors: Mark Erlander, Xiao-Jun Ma
-
Publication number: 20060286579Abstract: This invention provides gene sequence identities and methods for the determination of cellular gene expression and the comparison of expression levels between different gene sequences and between different cells. The gene sequences may be used as reference, normalization, or “housekeeping” gene sequences, the expression of which remains consistent in individual cells, even under different conditions, as well as among cells from different samples and origins.Type: ApplicationFiled: June 2, 2006Publication date: December 21, 2006Applicant: AviaraDx, Inc.Inventors: Mark Erlander, Xiao-Jun Ma
-
Publication number: 20060263806Abstract: Methods and compositions are provided for the detection of breast cancer based upon the identification of three biomarkers for non-normal breast cells. The biomarkers were identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer. Two biomarkers display increased expression in non-normal cells while the third biomarker displays decreased expression in non-normal cells.Type: ApplicationFiled: May 2, 2006Publication date: November 23, 2006Applicant: AviaraDx, Inc.Inventors: Xiao-Jun Ma, Dennis Sgroi, Mark Erlander
-
Publication number: 20060246434Abstract: A method of processing images includes the steps of retrieving a source image file including pixel date, creating a destination image file buffer, mapping the pixel data from the source image file to the destination image file buffer, and outputting pixel, data from the destination image file buffer as a destination image file. The step of mapping pixel data from the source image file to the destination image file buffer can include the step of interpolating the source image pixel data to produce pixel date for the destination image file buffer. Border pixel data can be added to the source image file to improve the efficiency interpolation step. The source image file can be a panoramic projection image file, and can include pixel data from a plurality of images. An apparatus for processing images in accordance with the method is also provided.Type: ApplicationFiled: March 14, 2003Publication date: November 2, 2006Inventors: Mark Erlander, Ranelle Salunga, Theresa Taylor, Liang You, Steven Kunitake
-
Publication number: 20060234287Abstract: Methods and compositions for the identification of breast cancer progression signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages of breast cancer.Type: ApplicationFiled: June 26, 2006Publication date: October 19, 2006Applicant: AviaraDx, Inc.Inventors: Mark Erlander, Xia-Jun Ma, Dennis Sgroi
-
Publication number: 20060154267Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of multiple biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while two other biomarkers display decreased expression correlated with tamoxifen response.Type: ApplicationFiled: March 24, 2005Publication date: July 13, 2006Applicant: Arcturus Bioscience, Inc.Inventors: Xiao-Jun Ma, Mark Erlander, Dennis Sgroi, Edward Enright
-
Patent number: 7049401Abstract: DNAs encoding the human histamine H3 receptor have been cloned and characterized. The recombinant protein is capable of forming biologically active histamine H3 receptor protein. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.Type: GrantFiled: August 21, 2000Date of Patent: May 23, 2006Assignee: Ortho McNeil Pharmaceutical, Inc.Inventors: Timothy W. Lovenberg, Mark Erlander, Arne Huvar, Jayashree Pyati
-
Publication number: 20060094035Abstract: The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.Type: ApplicationFiled: June 3, 2005Publication date: May 4, 2006Applicant: Arcturus Bioscience, Inc.Inventors: Mark Erlander, Xiao-Jun Ma
-
Publication number: 20060088851Abstract: This invention relates to the detection of increased expression from the HoxB13 (homeobox B13) gene as indicative of an invasive or metastatic cancer phenotype. The invention provides methods of detecting the level of expression from the HoxB13 gene, optionally in combination with nodal status, as an indicator of the invasive or metastatic phenotype as well as increased cellular migration and/or mobility. The invention also provides for the measurement of expression from the HoxB13 gene to assist in the determination of patient prognosis as well as clinical diagnosis and treatment.Type: ApplicationFiled: June 3, 2005Publication date: April 27, 2006Applicants: Arcturus Bioscience, Inc., General Hospital CorporationInventors: Mark Erlander, Dennis Sgroi, Xiao-Jun Ma
-
Publication number: 20060063170Abstract: This invention relates to the determination of RNA quality, or RNA integrity, in a biological sample. The extent of RNA degradation, or retention of RNA integrity, is determined based upon the comparison of the relative amount of two sequences of a representative RNA molecule in the sample. Compositions and methods related to the determination are provided to assess RNA quality.Type: ApplicationFiled: March 18, 2005Publication date: March 23, 2006Applicant: Arcturus Bioscience, Inc.Inventors: Mark Erlander, Li Ding
-
Publication number: 20050255481Abstract: The invention relates to the identification and use of sequences from expressed progesterone receptor transcripts in relation to breast cancer. In particular, the invention provides the identities of polynucleotide sequences that may be used to identify populations that are positive for estrogen receptor expression. The expressed polynucleotide sequences may be used in the study and/or diagnosis of cells and tissue in breast cancer as well as for the study and/or determination of prognosis of a patient.Type: ApplicationFiled: May 11, 2004Publication date: November 17, 2005Inventors: Xiao-Jun Ma, Edward Enright, Mark Erlander
-
Publication number: 20050239079Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to tamoxifen treatment. The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with ER+ breast cancer with tamoxifen. Additional methods and compositions are provided for predicting tamoxifen responsiveness in cases of ER+ breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.Type: ApplicationFiled: December 2, 2003Publication date: October 27, 2005Applicant: Arcturus Engineering, Inc.Inventors: Mark Erlander, Xiao-Jun Ma, Dennis Sgroi
-
Publication number: 20050239083Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.Type: ApplicationFiled: February 6, 2004Publication date: October 27, 2005Applicant: Arcturus Bioscience, Inc.Inventors: Mark Erlander, Xiao-Jun Ma, Dennis Sgroi
-
Publication number: 20050208500Abstract: The invention relates to the identification and use of gene expression profiles, or patterns, suitable for identification of populations that are positive and negative for estrogen receptor expression. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats, and may be used in the study and/or diagnosis of cells and tissue in breast cancer as well as for the study and/or determination of prognosis of a patient, including breast cancer survival.Type: ApplicationFiled: March 4, 2004Publication date: September 22, 2005Inventors: Mark Erlander, Xiao-Jun Ma, Wei Wang, James Wittliff
-
Publication number: 20050164342Abstract: cDNA molecules coding for GAD65 polypeptide. The invention provides cDNA molecules comprising a part of the cDNA sequence of GAD65 which encode at least one epitope for autoantibodies to GAD65. The invention also provides cloning vehicles capable of replication and expression comprising cDNA molecules coding for GAD65. The invention further provides for hosts transformed with a vehicle having a cDNA molecule coding for GAD65. In another embodiment, the invention provides for the detection of autoantibodies to GAD65 using the GAD65 polypeptides coded for by the cDNA molecules of the invention.Type: ApplicationFiled: August 15, 2003Publication date: July 28, 2005Inventors: Allan Tobin, Mark Erlander, Daniel Kaufman
-
Publication number: 20050130194Abstract: The present invention provides methods for the amplification of nucleic acid molecules. Methods for amplifying target polynucleotides, including mRNA, using oligonucleotides, DNA and RNA polymerases are provided. The invention further provides compositions and kits for practicing the methods, as well as methods which use the amplification products.Type: ApplicationFiled: September 15, 2004Publication date: June 16, 2005Applicant: Arcturus Bioscience, Inc.Inventors: Mark Erlander, Ranelle Salunga
-
Publication number: 20050124795Abstract: DNA encoding human 5-HT3-C has been cloned and characterized. The recombinant protein is capable of forming biologically active human 5-HT3-C protein. The cDNA has been expressed in recombinant host cells that produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.Type: ApplicationFiled: September 12, 2003Publication date: June 9, 2005Inventors: Adrienne Dubin, Mark Erlander, Arne Huvar, Rene Huvar, Lukas Buehler
-
Publication number: 20050100933Abstract: The invention provides for the identification and use of gene expression profiles, or patterns, with clinical relevance to breast cancer. In particular, the invention provides the identities of genes that are correlated with patient survival and breast cancer recurrence. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats and used to predict the survival of subjects afflicted with breast cancer and to predict breast cancer recurrence and. The profiles may also be used in the study and/or diagnosis of breast cancer cells and tissue, including the grading of invasive breast cancer, as well as for the study and/or determination of prognosis of a patient. When used for diagnosis or prognosis, the profiles may be used to determine the treatment of breast cancer based upon the likelihood of life expectancy and recurrence.Type: ApplicationFiled: June 18, 2004Publication date: May 12, 2005Applicant: Arcturus Bioscience, Inc.Inventors: Mark Erlander, Xiao-Jun Ma, Wei Wang, James Wittliff
-
Publication number: 20050095607Abstract: The invention relates to the identification and use of gene expression profiles, or patterns, suitable for identification of breast cancer patient populations with different survival outcomes. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats, and may be used in the study and/or determination of the prognosis of a patient, including breast cancer survival.Type: ApplicationFiled: March 5, 2004Publication date: May 5, 2005Inventors: Mark Erlander, Xiao-Jun Ma, Wei Wang, James Wittliff